Wells Fargo & Company Celldex Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 22,411 shares of CLDX stock, worth $591,650. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,411
Previous 22,736
1.43%
Holding current value
$591,650
Previous $841,000
9.51%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$244 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$124 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$102 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$91.3 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$88 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.23B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...